NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
Clinical Trials
13 trialsNCT00446082 2020-12-21
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Novartis
Phase 1 Completed
NCT02354508 2019-12-10
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis
Phase 3 Completed
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT01137682 2018-04-05
PAOLA
Novartis
Phase 3 Completed
NCT02299089 2017-12-15
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)
Camurus AB
Phase 2 Completed
NCT00376064 2017-03-06
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
Novartis
Phase 4 Completed
NCT00171886 2017-02-24
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Novartis
Phase 4 Completed
NCT01029275 2014-07-31
SAPORO
University Hospital, Rouen
Phase NA Completed
NCT00001860 2008-03-04
Sandostatin LAR Depot vs. Surgery for Treating Acromegaly
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00017927 2008-03-04
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00627796 2008-03-03
ATG1line
Federico II University
Phase 4 Completed
NCT00461149 2007-04-17
HDacro
Federico II University
Phase 4 Completed